Drug Trial Radar · NCT04017845
Screening for Colorectal Cancer in Average and High Risk Population
Last checked: Nov 19, 2026Latest source record: Sep 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
537
Actual
Start
Apr 1, 2015
Primary completion
May 30, 2017
Study completion Oct 30, 2017
Sponsor
- Lead sponsor
- Lewai Sharki Abdulaziz, MSc PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Research & Development Directorate, Ministry of Higher Education, Iraq; Al-Kindy College of Medicine
- First posted
- Jul 12, 2019
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The existing evidence from epidemiological studies and randomized controlled trials has consistently assures the cost effectiveness and the influential role of screening in reducing incidence rates and deaths caused by Colorectal Cancer (CRC). Population based organized screening programmes, which should be considered an obligation that is not to be postponed, require valuable information that can be reliably extrapolated from well-designed pilot study conducted prior to programme implementation. The main objectives of the current pilot CRC screening project, named after "Al-Kindy College of Medicine", was to evaluate and explore the specific aspects of the intended population-based organized CRC screening programme, including: barriers affecting adherence to the programme, performance indicators of the proposed screening programme, the target population in which CRC screening is a legitimate healthcare priority, quality assurance of screening tests and colonoscopy services, and to propose an algorithm that will provide a clinically and logistically acceptable positivity rate.
Conditions
- Colorectal Neoplasms
- Colorectal Cancer
- Adenomatous Polyp of Colon
Interventions
FITDiagnostic test
Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
Precolonoscopy cleansing regimenProcedure
Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
Conventional ColonoscopyProcedure
With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions \<25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
Histopathological examinations of screen-detected lesionsDiagnostic test
Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: \>10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
Tribenoside 400 mg + lidocaine 40 mg suppositoriesDrug
Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
Diltiazem hydrochloride 2%/Nitroglycerin rectal ointmentDrug
Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- prevalence of causes accounting for population disagreement to participate in screening. programme.Time frame: Documented on one occasion, during invitation interview as an act on disagreement to participate in the screening programme.
- Prevalence of CRC risk factors and risk stratification in target population.Time frame: Documented on one occasion, during invitation interview, as an act on agreement to participate in the screening programme.
- Performance Indicators of Fecal Immunochemical Test (FIT)Time frame: Documented on one occasion, immediately after completion of FIT testing.
- Performance Indicators of Colonoscopic ExaminationTime frame: Documented on one occasion, immediately after completion of colonoscopy examination.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lewai S Abdulaziz
Baghdad, Iraq
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.